Iovance Biotherapeutics (IOVA) Common Equity (2016 - 2025)
Historic Common Equity for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to $702.3 million.
- Iovance Biotherapeutics' Common Equity fell 920.13% to $702.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $702.3 million, marking a year-over-year decrease of 920.13%. This contributed to the annual value of $710.4 million for FY2024, which is 2151.71% up from last year.
- Per Iovance Biotherapeutics' latest filing, its Common Equity stood at $702.3 million for Q3 2025, which was down 920.13% from $698.5 million recorded in Q2 2025.
- Iovance Biotherapeutics' 5-year Common Equity high stood at $773.5 million for Q3 2024, and its period low was $578.6 million during Q2 2023.
- Its 3-year average for Common Equity is $691.4 million, with a median of $698.5 million in 2025.
- Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 3283.46% in 2024, then plummeted by 920.13% in 2025.
- Quarter analysis of 3 years shows Iovance Biotherapeutics' Common Equity stood at $584.6 million in 2023, then rose by 21.52% to $710.4 million in 2024, then decreased by 1.14% to $702.3 million in 2025.
- Its last three reported values are $702.3 million in Q3 2025, $698.5 million for Q2 2025, and $767.9 million during Q1 2025.